Glucotrack (GCTK, Financials) announced the pricing of a $3 million public offering of approximately 2.6 million shares of common stock. GlucoTrack stock fell 31% to $0.56 as of 11:45 a.m. ET on Wednesday.
At $1.15 a share, the offering is being done on a "best efforts" basis. Subject to usual circumstances, the business anticipates the deal to conclude on or around Feb. 5.
The only placement agent for the transaction is Dawson James Securities, Inc. Glucotrack said that the offering is being carried out under a previously filed registration statement on Form S-3, which the U.S. Securities and Exchange Commission deemed effective on Oct. 3, 2024.
The firm is focused on creating implanted continuous glucose monitoring systems for diabetics. Designed for long-term usage, its system does not need an on-body wearable component and has a sensor lifetime of up to three years.
The public offering of Glucotrack reflects continuous attempts to raise money for regulatory approval and product development. The corporation acknowledged the risks related to distribution agreements, regulatory clearances, and the need for more funds for future filings.
This article first appeared on GuruFocus.免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。